GoodRx (NASDAQ:GDRX) Price Target Cut to $5.00 by Analysts at The Goldman Sachs Group

GoodRx (NASDAQ:GDRX) had its price target lowered by The Goldman Sachs Group from $6.00 to $5.00 in a research note issued to investors on Friday,Benzinga reports. The Goldman Sachs Group currently has a neutral rating on the stock.

Several other research analysts also recently commented on GDRX. Citigroup decreased their target price on shares of GoodRx from $7.00 to $6.25 and set a “buy” rating on the stock in a research note on Friday, January 10th. Truist Financial decreased their price objective on shares of GoodRx from $6.50 to $5.50 and set a “hold” rating on the stock in a research report on Thursday, April 10th. Finally, Wells Fargo & Company dropped their target price on shares of GoodRx from $8.00 to $7.00 and set an “overweight” rating for the company in a report on Tuesday, April 29th. Five equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $7.60.

GoodRx Stock Up 2.8%

Shares of NASDAQ:GDRX opened at $4.36 on Friday. The stock has a market capitalization of $1.67 billion, a P/E ratio of -145.33, a price-to-earnings-growth ratio of 2.46 and a beta of 1.24. The stock’s 50-day moving average price is $4.49 and its 200-day moving average price is $4.72. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. GoodRx has a 12-month low of $3.68 and a 12-month high of $9.26.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.05. The business had revenue of $202.97 million for the quarter, compared to analyst estimates of $202.25 million. GoodRx had a positive return on equity of 5.35% and a negative net margin of 2.05%. GoodRx’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period last year, the company earned $0.08 EPS. On average, equities analysts anticipate that GoodRx will post 0.13 earnings per share for the current year.

Institutional Investors Weigh In On GoodRx

A number of large investors have recently modified their holdings of GDRX. National Bank of Canada FI raised its holdings in GoodRx by 34.9% in the fourth quarter. National Bank of Canada FI now owns 8,308 shares of the company’s stock worth $39,000 after purchasing an additional 2,151 shares in the last quarter. Hohimer Wealth Management LLC grew its position in shares of GoodRx by 8.2% in the 1st quarter. Hohimer Wealth Management LLC now owns 35,218 shares of the company’s stock worth $155,000 after buying an additional 2,658 shares during the period. SBI Securities Co. Ltd. grew its position in shares of GoodRx by 13.8% in the 1st quarter. SBI Securities Co. Ltd. now owns 22,624 shares of the company’s stock worth $100,000 after buying an additional 2,748 shares during the period. Gotham Asset Management LLC increased its stake in shares of GoodRx by 31.0% in the 4th quarter. Gotham Asset Management LLC now owns 17,677 shares of the company’s stock worth $82,000 after acquiring an additional 4,182 shares in the last quarter. Finally, Gagnon Securities LLC lifted its position in GoodRx by 9.9% during the 4th quarter. Gagnon Securities LLC now owns 69,867 shares of the company’s stock valued at $325,000 after acquiring an additional 6,266 shares during the period. Institutional investors own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.